News MedicalBlood Pressure Drug Losartan Boosts Metabolism by Stimulating Brown Fat

⚠️ Early Stage / Preclinical Research

Researchers examined brown adipose tissue across PET/CT scans from more than 100,000 patients and found favorable cardiometabolic patterns among those with detectable brown fat. ARB use was also associated with greater brown-fat activity. Follow-up experiments showed losartan directly increased metabolic activity in cultured brown-fat cells, while treated mice demonstrated increased energy expenditure, oxygen consumption, and carbon dioxide production without weight change. The findings raise a potential drug-repurposing hypothesis but do not demonstrate metabolic benefit from losartan in patients.

Clinical Considerations

• Greater brown-fat activity was associated with better glycemic, lipid, echocardiographic, and inflammatory measures in the imaging cohort.
• Brown-fat location appeared relevant, with higher axillary activity associated with lower prevalence of hypertension.
• Patients taking angiotensin receptor blockers had greater brown-fat activity, an observational association that did not establish a drug effect.
• Losartan directly increased brown-fat metabolic activity in cultured cells through molecular mechanisms distinct from its blood-pressure effects.
• In healthy mice, losartan increased energy expenditure and gas exchange while body weight remained stable.
• The study also found exploratory associations between brown fat and psychiatric diagnoses, but these findings do not establish a protective effect.

Practice Applications

• Interpret the losartan findings as mechanistic and hypothesis-generating rather than evidence for metabolic treatment.
• Avoid extrapolating cell or mouse findings to weight management or prescribing losartan specifically to activate brown fat.
• Recognize brown adipose tissue as an emerging metabolic research target associated with favorable cardiometabolic measures in this cohort.
• Monitor future human studies assessing whether losartan or related pathways meaningfully alter brown-fat activity and clinical outcomes.